Effects of Preoperative Aspirin on Cardiocerebral and Renal Complications in Non-Emergent Cardiac Surgery Patients: A Sub-Group and Cohort Study
Authors:
Open Access
- 2 February 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (2) , e30094
Abstract
Postoperative cardiocerebral and renal complications are a major threat for patients undergoing cardiac surgery. This study was aimed to examine the effect of preoperative aspirin use on patients undergoing cardiac surgery. An observational cohort study was performed on consecutive patients (n = 1879) receiving cardiac surgery at this institution. The patients excluded from the study were those with preoperative anticoagulants, unknown aspirin use, or underwent emergent cardiac surgery. Outcome events included were 30-day mortality, renal failure, readmission and a composite outcome - major adverse cardiocerebral events (MACE) that include permanent or transient stroke, coma, perioperative myocardial infarction (MI), heart block and cardiac arrest. Of all patients, 1145 patients met the inclusion criteria and were divided into two groups: those taking (n = 858) or not taking (n = 287) aspirin within 5 days preceding surgery. Patients with aspirin presented significantly more with history of hypertension, diabetes, peripheral arterial disease, previous MI, angina and older age. With propensity scores adjusted and multivariate logistic regression, however, this study showed that preoperative aspirin therapy (vs. no aspirin) significantly reduced the risk of MACE (8.4% vs. 12.5%, odds ratio [OR] 0.585, 95% CI 0.355–0.964, P = 0.035), postoperative renal failure (2.6% vs. 5.2%, OR 0.438, CI 0.203–0.945, P = 0.035) and dialysis required (0.8% vs. 3.1%, OR 0.230, CI 0.071–0.742, P = 0.014), but did not significantly reduce 30-day mortality (4.1% vs. 5.8%, OR 0.744, CI 0.376–1.472, P = 0.396) nor it increased readmissions in the patients undergoing cardiac surgery. Preoperative aspirin therapy is associated with a significant decrease in the risk of MACE and renal failure and did not increase readmissions in patients undergoing non-emergent cardiac surgery.Keywords
This publication has 34 references indexed in Scilit:
- Platelet-Directed Therapies and Coronary Artery Bypass GraftingThe American Journal of Cardiology, 2009
- Antiplatelet therapy and coronary artery bypass graft surgery: perioperative safety and efficacyExpert Opinion on Drug Safety, 2009
- Guideline on antiplatelet and anticoagulation management in cardiac surgeryEuropean Journal of Cardio-Thoracic Surgery, 2008
- 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary InterventionCirculation, 2008
- Myocardial infarction following coronary artery bypass graft surgery increases healthcare resource utilizationCritical Care Medicine, 2007
- ACC/AHA 2004 Guideline Update for Coronary Artery Bypass Graft Surgery: Summary ArticleCirculation, 2004
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic strokeThe Lancet, 1997
- Optimal antithrombotic therapy following aortocoronary bypass: A meta-analysisEuropean Journal of Cardio-Thoracic Surgery, 1993
- A Platelet-Inhibitor-Drug Trial in Coronary-Artery Bypass OperationsNew England Journal of Medicine, 1982